CJC-1295 with DAC

Mechanism of Action

CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. The key distinguishing feature is the Drug Affinity Complex (DAC), a lysine-linked maleimidopropionic acid group that binds to serum albumin.

How the DAC Modification Works

Albumin Binding

The DAC moiety covalently binds to circulating albumin after injection:

• Creates a depot effect extending half-life dramatically
• Prevents rapid proteolytic degradation
• Results in sustained, elevated GH levels rather than pulsatile release

GHRH Receptor Activation

CJC-1295 binds to GHRH receptors on pituitary somatotrophs:

• Stimulates cAMP pathway activation
• Increases GH synthesis and secretion
• Maintains feedback sensitivity (unlike exogenous GH)

Physiological Effects

Growth Hormone Elevation

• Sustained 2-3x elevation of baseline GH levels
• IGF-1 levels increase correspondingly
• Effects persist for 6-8 days post-injection

Metabolic Effects

• Enhanced lipolysis and fat oxidation
• Increased protein synthesis
• Improved nitrogen retention

Tissue Effects

• Supports muscle protein synthesis
• May enhance connective tissue repair
• Potential benefits for bone density

Comparison with Non-DAC Variant

Research & Evidence

Human Studies

Phase I/II Trials

Early clinical trials examined CJC-1295 DAC for GH deficiency:

• Single-dose studies showed sustained GH elevation for up to 14 days
• IGF-1 levels increased by 40-100% above baseline
• Generally well-tolerated in healthy subjects

Pharmacokinetic Studies

Human PK data confirmed the extended half-life:

• Terminal half-life of 5.8-8.1 days
• Peak GH levels at 24-48 hours post-injection
• Dose-dependent IGF-1 response

Animal Studies

GH Secretion Studies

Research in various animal models demonstrated:

• Robust and sustained GH elevation
• Preserved pulsatile GH secretion pattern (blunted but not eliminated)
• No desensitization with repeated dosing over 6 weeks

Metabolic Effects

Animal studies showed metabolic benefits:

• Reduced adipose tissue mass
• Improved lean body mass
• Enhanced glucose disposal (acute) but impaired tolerance (chronic)

Limitations of Current Evidence

• No Phase III trials completed
• Development discontinued for undisclosed reasons
• Long-term safety data lacking
• Most research is 10+ years old

Dosing

Research Protocols

Administration Guidelines

Injection Technique

• Subcutaneous injection in abdomen, thigh, or deltoid area
• Rotate injection sites
• Evening administration may better align with natural GH rhythm

Reconstitution

• Use bacteriostatic water for reconstitution
• Typical: 2mg vial + 1ml BAC water = 2mg/ml
• Gently swirl, do not shake
• Store refrigerated after reconstitution

Important Considerations

Continuous vs Pulsatile GH

The DAC version produces sustained GH elevation rather than natural pulsatile release:

• May be less physiological than non-DAC variant
• Some researchers prefer non-DAC for more natural GH pattern
• Long-term implications of sustained elevation unknown

Cycling Recommendations

Due to the sustained nature:

• Consider 8-12 week cycles
• Allow washout periods between cycles
• Monitor IGF-1 levels to guide cycling

Pharmacokinetics

Absorption

• Subcutaneous: Well absorbed; bioavailability approximately 90%
• Peak peptide levels: 2-4 hours post-injection
• Peak GH response: 24-48 hours post-injection

Distribution

• Extensive albumin binding (the DAC mechanism)
• Large apparent volume of distribution due to albumin complex
• Tissue distribution follows albumin kinetics

Metabolism

• Gradual release from albumin complex
• Peptide portion subject to proteolytic degradation
• Hepatic metabolism of fragments

Elimination

• Terminal half-life: 6-8 days
• Primarily renal elimination of metabolites
• No significant accumulation with weekly dosing
• Steady state achieved by 3-4 weeks

Synergy & Stacking

GHRH + GHRP Combinations

With Ipamorelin

The classic combination of GHRH + GHRP:

• CJC-1295 DAC provides sustained GHRH stimulation
• Ipamorelin adds pulsatile GHRP stimulus
• Combined effect greater than either alone
• Note: Many prefer non-DAC CJC-1295 for this combination

With GHRP-6 or GHRP-2

Alternative GHRP options:

• Greater GH release than ipamorelin
• More side effects (hunger with GHRP-6)
• Consider goals and tolerance

With MK-677

Oral GHS Addition

• MK-677 provides daily oral GH stimulation
• CJC-1295 DAC adds weekly injectable boost
• May be redundant for some users
• Monitor for excessive IGF-1 elevation

With Healing Peptides

BPC-157 or TB-500

• No direct pharmacological interaction
• Enhanced GH environment may support healing
• Popular combination for recovery protocols

Timing Considerations

• CJC-1295 DAC: Evening injection preferred
• If combining with GHRP: Some inject simultaneously
• MK-677: Typically taken at bedtime
• Healing peptides: Timing based on their protocols

Safety & Side Effects

Common Side Effects

Injection Site Reactions (frequent)

• Redness, swelling at injection site
• Usually mild and transient
• Rotate injection sites

Water Retention (common)

• Mild edema, particularly in extremities
• Usually resolves with continued use
• May indicate excessive GH elevation

Flushing/Warmth (common)

• Facial flushing post-injection
• Sensation of warmth
• Generally transient

Less Common Side Effects

Metabolic Effects

• Increased hunger
• Transient hyperglycemia
• Insulin resistance with prolonged use

Musculoskeletal

• Joint stiffness or mild pain
• Carpal tunnel-like symptoms
• Typically dose-related

Serious Concerns

Sustained GH Elevation Risks

• Unlike pulsatile release, continuous elevation may carry additional risks
• Potential for accelerated tumor growth in those with occult malignancy
• Long-term cardiovascular effects unknown

Glucose Dysregulation

• Can worsen or unmask diabetes
• Monitor fasting glucose regularly
• May require diabetes medication adjustment

Monitoring

Baseline Assessments

Before initiating any protocol:

• IGF-1 level (primary marker)
• Fasting glucose and HbA1c
• Lipid panel
• Complete blood count
• Liver and kidney function
• Consider baseline imaging if clinically indicated

During Protocol

Monthly Monitoring

• IGF-1 levels (target: upper normal range)
• Fasting glucose
• Symptom assessment

Periodic Monitoring (every 3 months)

• HbA1c if glucose elevated
• Lipid panel
• Liver function

Target Ranges

Post-Protocol

• Allow 4 weeks for complete washout
• Recheck IGF-1 to confirm return to baseline
• Assess for any persistent effects

Regulatory Status

Current Status by Region

Anti-Doping Considerations

CJC-1295 (with or without DAC) is explicitly prohibited by WADA:

• Listed under S2: Peptide Hormones, Growth Factors
• Prohibited at all times (in and out of competition)
• Detectable in urine for extended periods due to long half-life

Quality and Sourcing

• No pharmaceutical-grade product available
• Research chemical quality varies significantly
• Third-party testing recommended
• Counterfeit and underdosed products common

References